Absci Corporation (ABSI) Announces First Participants Dosed In Phase 1/2a HEADLINE Trial

Absci Corporation (NASDAQ:ABSI) is among the 12 Best Genomics Stocks to Invest In.

Absci Corporation (NASDAQ:ABSI) announced on December 4, 2025, that the first healthy volunteers had been dosed in the Phase 1/2a HEADLINE clinical trial investigating ABS-201, an experimental anti-prolactin receptor antibody built on its generative AI system. The Phase 1/2a trial is intended to evaluate effectiveness, pharmacokinetics, pharmacodynamics, immunogenicity, safety, and tolerability. The trial’s interim results are anticipated in the latter part of 2026. As per the company, ABS-201, which addresses indications in women’s health and dermatology, is a progression of its strategy to take internally produced assets into clinical development. According to founder and CEO Sean McClain, the achievement underlines the use of the AI-driven platform for clinical development and improves the delivery of unique assets.

Following an investor event centered on ABS-201 and its androgenetic alopecia program, the Fly reported on December 17, 2025, that H.C. Wainwright increased its price objective on Absci Corporation (NASDAQ:ABSI) to $8 from $7 and retained a Buy rating. The firm included ABS-201 in its financial model and noted how it might raise the percentage of hair follicles in the growth phase as opposed to the resting period, which is when hair loss takes place. The analyst stated that the strength of the preclinical evidence given throughout the event lends credibility to the ABS-201 program.

Absci Corporation (NASDAQ:ABSI) is an artificial intelligence-powered synthetic biology firm that is unlocking proteins’ potential as the next generation of drugs.

While we acknowledge the potential of ABSI as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025.

Disclosure. None